NovoCure : Financial Reports 2026 novocure corporate responsibility report
NVCR
Published on 04/21/2026 at 10:52 am EDT
table of contents
introduction
overview
patients
employees
communities & environment
corporate governance & ethics
quality & safety 40
appendix 45
2026 Novocure corporate responsibility report 2
INTRODUCTION OVERVIEW PATIENTS EMPLOYEES COMMUNITIES & ENVIRONMENT CORPORATE GOVERNANCE & ETHICS QUALITY & SAFETY APPENDIX
letter from the CEO
At Novocure, our mission to extend survival in some of the most aggressive forms of cancer is one that challenges us every day.
Patients and their families place extraordinary trust in Novocure. This responsibility requires we demonstrate unwavering integrity in everything we do for patients, healthcare providers, employees, communities, partners, and shareholders.
Through our 2026 Corporate Responsibility report we are able to share the many ways we put our commitment to act as an ethical and trusted partner into action. We have established expectations for the way we work at Novocure and with communities and stakeholders outside of our organization.
In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advancing the treatment of cancer with our technology.
As we continue to grow, we will have the opportunity to serve new patients and su more physicians as they utilize TTFields therapy. We have built an organization prepared to take on these challenges, while remaining dedicated to our core values that have guided us to this point.
pport
se e
heir yees, he
your
Within the pages of the Corporate Responsibility report you will see images of employees, patients and partners. The images represent the many groups we ar indebted to and who I hope will continue to hold us to the highest expectations of ethical behavior.
In closing, I want to thank our patients, t caregivers, patient advocates, our emplo partners, shareholders and members of t communities where we live and work for continued trust in Novocure.
Sincerely,
Frank Leonard,
Chief Executive Officer
2026 Novocure corporate responsibility report 3
Yoram Palti, M.D., Ph.D., Founder
overview
who we are
Novocure is a global oncology company of more than 1,500 dedicated employees working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields).
our founder
Professor Yoram Palti of the Technion, Israel Institute of Technology founded Novocure in 2000.
Prof Palti was an expert in biophysics and he developed a new way to treat solid tumor cancers using electric fields that could destroy cancerous tumor cells while sparing healthy cells.
His innovative approach to cancer treatment led to the development of TTFields therapy, which has been approved to treat advanced brain, lung and pancreatic cancers. Professor Palti passed away in January 2026. His work is responsible for extending the lives of tens of thousands of patients around the world. It is this legacy that continues to guide and inspire our team.
At Novocure, we remain committed to Prof Palti's vision and the patient-forward mission he inspired that guides our work.
To learn more about the history of Novocure, visit our website
2026 Novocure corporate responsibility report 4
our values
Innovation
Our founders created a different way to fight cancer.
We channel that founding spirit into our science, business and patient relationships to deliver innovative and proven solutions designed to advance cancer care.
Focus
We dream big. But we also know that in order to achieve our aspirations, we must be intentional every day in how we spend our time, energy and resources.
Drive
Patients and their families are at the heart of our mission. Our passion for making a difference in the lives of cancer patients fuels us in our day-to-day work and guides us in our decision-making.
Courage
It takes courage to innovate. We stand alongside our patients and stand up for them by challenging the status quo.
Trust
Our patients trust us as an integral part of their cancer care team. We trust ourselves and our colleagues to act with integrity and accountability as we use our individual strengths to work together efficiently and effectively in pursuit of our patient-forward mission.
Empathy
Confronting cancer is physically, mentally and emotionally challenging. We put ourselves in the shoes of our patients, their families, health care providers, researchers and our colleagues as we strive to change the way cancer is treated.
2026 Novocure corporate responsibility report 5
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
our mission
Together with our patients, we strive to extend survival in some of the most
aggressive forms of cancer by developing and commercializing our innovative therapy.
INTRODUCTION OVERVIEW PATIENTS EMPLOYEES COMMUNITIES & ENVIRONMENT CORPORATE GOVERNANCE & ETHICS QUALITY & SAFETY APPENDIX
What are Tumor Treating Fields?
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via multiple, distinct mechanisms. Electric fields have different effects on the human body depending on their frequency. Because cancer cells contain electrically charged components, they can be influenced by electric fields.
Due to its multi-mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and in preclinical models it demonstrated enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies. TTFields therapy provides clinical versatility that has the
potential to help address treatment challenges across a range of solid tumors.
TTFields do not significantly affect healthy cells because healthy cells have different properties (including division rate, morphology, and electrical properties) than cancer cells.
DISRUPTION OF MITOSIS
In preclinical models, TTFields have been shown to disrupt mitosis in cancer cells by exerting electric forces on their polar components (e.g., microtubule spindle formation during mitosis), disrupting their normal localization (place in cell membrane) and function, ultimately leading to cell death.
INTERFERENCE WITH CELL
MOVEMENT AND MIGRATION
In preclinical models, TTFields have been shown to
alter the organization and dynamics of the cytoskeleton, disrupting cancer cell motility and migration, which are essential for metastasis.
TTFields disrupt the direction and diminish the abundance of the microtubule network, interfering with cancer cell migration.
ENHANCEMENT OF ANTITUMOR IMMUNITY
In pre-clinical models, TTFields-mediated cell disruption has been shown to activate the immune system
and induce a downstream immunogenic anti-tumor response.
TUMOR CELL HEALTHY CELL
DOWNREGULATION OF DNA DAMAGE RESPONSE
To learn more about the capabilities of Tumor Treating Fields, visit https://www.novocure.com/ttfields.
In preclinical models, TTFields have been shown to downregulate important DNA damage response.
2026 Novocure corporate responsibility report 6
How are Tumor Treating Fields delivered?
TTFields are generated through a portable medical device and delivered through two pairs of arrays that are placed directly on a patient's skin. These arrays create two alternating electric fields to help ensure optimal coverage of the impacted area.
The portable TTFields device is powered with a rechargeable lithium-ion battery and can also be connected to a direct power supply.
TTFIELDS ARE APPROVED TO TREAT SEVERAL CANCER TYPES AND ARE MARKETED UNDER THESE BRAND NAMES:
Optune Gio is commercially available for the treatment of adult patients with glioblastoma
(or WHO grade 4 glioma in the EU) in 14 countries: Austria, Canada, China (in partnership with Zai Lab), Czechia, France, Germany, Israel, Italy, Japan, Spain, Sweden, Switzerland, the United Kingdom and the United States.
Optune Lua is commercially available for the treatment of adult patients with non-small cell lung cancer in Germany, Japan and the United States, and for the treatment of adult patients with (malignant pleural) mesothelioma in Germany, the United States, and certain other countries.
Optune Pax is commercially available for the treatment of adult patients with locally
advanced pancreatic cancer in the United States.
2026 Novocure corporate responsibility report 7
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
our global footprint
Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel.
SWEDEN
CANADA
UNITED STATES
GERMANY UK
FRANCE SPAIN
CZECHIA AUSTRIA
SWITZERLAND ITALY
ISRAEL
GREATER CHINA
JAPAN
Greater China is in partnership with Zai Lab
4,600+
ACTIVE PATIENTS ON THERAPY*
40,000+
PATIENTS TREATED TO DATE*
$655M
ANNUAL NET REVENUE (2025)
1,500+
EMPLOYEES WORLDWIDE*
*As of January 2026.
2026 Novocure corporate responsibility report 8
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
our approach to corporate responsibility
Board of Directors
Role: Oversight of strategy and reporting (Nominating and Governance Committee)
Executive Leadership Team
Role: Strategy development, goal setting and implementation
Corporate Responsibility Management Committee
Role: Leadership and strategy review
(Executive sponsor: Chief Financial Officer, Christoph Brackmann)
ADVOCACY
HUMAN
RESOURCES
LEGAL OPERATIONS
PATIENT
EXPERIENCE
QUALITY
SAFETY
Our dedication to corporate responsibility, including environmental, social and governance issues, is integral to the success of our patient-forward mission.
This is our sixth annual Corporate Responsibility report. Since we began publishing this report, our strategy and reporting standards have evolved to integrate more information and data from a variety of sources, as well as feedback from our numerous stakeholders. What has not changed is our uncompromising expectation that we act with integrity, honesty, transparency, and good intention with all stakeholders:
We provide personalized, hands-on support to each of our patients throughout their therapy experience
We created a support structure to help employees make great strides toward advancing cancer care
We provide opportunities for our team to support the places and people where we live in work
We have defined governance and implemented oversight at all levels of our organization to cultivate trust with our stakeholders
We utilize multiple frameworks and guiding principles to help focus our reporting efforts. These principles include the United Nations Principles on Business and Human Rights and the Sustainability Accounting Standards Board reporting framework (see appendix).
Unless otherwise specified, this report reflects developments as of March 31, 2026.
2026 Novocure corporate responsibility report 9
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
Jovan, living with glioblastoma in Minnesota
patients
Access to Therapy
Patient Engagement Programs
Device Support Specialists and MyNovocure
Product Innovation
2026 Novocure corporate responsibility report 10
INTRODUCTION OVERVIEW PATIENTS EMPLOYEES COMMUNITIES & ENVIRONMENT CORPORATE GOVERNANCE & ETHICS QUALITY & SAFETY APPENDIX
Our business model is designed to enable our team to provide the best possible care to our patients.
We are able to engage directly with our patients and their caregivers at every step in their TTFields therapy journey - beginning with their patient onboarding, through the therapy start and regularly throughout their treatment experience.
We believe the relationship between our employees and patients is unique. It offers us the opportunity to hear from patients about ways we can improve. These insights help us keep our patients' well-being at the forefront of our decisions.
access to therapy
Access to our therapy is a priority for us, our patients and the people who care about them. Once a patient is prescribed TTFields therapy, we partner directly with them to ensure therapy is made available as soon as possible. We are able to
engage with commercial or government payers on a patient's behalf, which allows us to leverage our expertise to help navigate coverage discussions.
In most of our active markets, we bear the financial risk for securing payment from payers. As of December 31, 2025, 97% of our active patients were able to benefit from insurance coverage of our therapy.
In certain cases of patient need, we provide treatment at no charge under our charitable care policy. Because we do not pursue collection of amounts
determined to qualify as charitable care, we do not report revenue associated with these treatments, and the cost of care is included in our total cost of goods sold. In 2025, we provided over $8 million in charitable care to patients in need.
Kyle, living with glioblastoma in Georgia
2026 Novocure corporate responsibility report 11
patient engagement programs
We offer a number of educational and experiential resources to potential patients and their families that explain in more detail how TTFields therapy works, how it can
fit into daily life, and ways they can connect with current patients to share their experiences.
OPEN HOUSES
Two-hour live events held throughout the year for patients and their caregivers considering or new to Optune Gio. At Open Houses, Optune Ambassadors share their stories and are available for question-and-answer sessions.
One of the key resources in the United States is our Ambassador program. Ambassadors are patients currently using Optune Gio or their caregivers. These Optune Gio Ambassadors offer the perspective that can only be obtained through first-hand experience. Ambassadors share their personal experiences with patients or caregivers who may be new to one of our devices (Optune Gio, Optune Lua, or Optune Pax) or are still evaluating their options following diagnosis. Optune Gio Ambassadors provide their unique insight into the day-to-day use of our therapy and how it can be integrated into daily routines.
Optune Gio Ambassadors play an important role in several of the other resources we offer prospective patients:
OPTUNE GIO WEBINARS
More than 20 held in 2025, these virtual engagements allow patients considering or who are new to our treatments to learn more about TTFields therapy.
Webinars are conducted monthly and provide a live forum for Optune Gio users to connect and share their experiences.
BUDDY CALLS
Direct one-on-one connections between prospective patients and an Optune Gio Ambassador. More than 250 calls were completed in 2025.
The goal of these programs is to support existing and potential patients and offer
real-life personal perspectives about using Optune Gio.
Mike, living with glioblastoma in Florida
2026 Novocure corporate responsibility report
12
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
INTRODUCTION OVERVIEW PATIENTS EMPLOYEES COMMUNITIES & ENVIRONMENT CORPORATE GOVERNANCE & ETHICS QUALITY & SAFETY APPENDIX
device support specialists and MyNovocure
We recognize that a cancer diagnosis can create extreme stress for patients and their families. With this in mind,
we have structured our business to provide support to patients throughout their treatment journey. We believe this unique model enables our team to provide the best possible care to our patients.
Once a patient has decided to utilize TTFields therapy, our team connects with the patient and caregiver to schedule a therapy start date. When the start date arrives, a member of our Device Support Specialist (DSS) team travels to the patient's home or their other preferred setting to teach the patient and caregivers about proper usage of the device.
This includes an overview of the device, discussion of skin care to ensure optimal comfort, training of caregivers, and proactive discussion of techniques to make the therapy process as seamless as possible. Following the start date, the DSS team maintains regular contact to provide technical support to the patient and caregiver throughout their TTFields therapy journey and answer questions related to the TTFields therapy kit- while the treating physician remains the contact for all medical questions.
In addition to regular check-ins with the DSS team, patients can rely on the on-call MyNovocure team for resources and assistance throughout their therapy experience. MyNovocure can help with insurance support, device troubleshooting, device training, tips for integrating treatment into daily life, resources for traveling while using TTFields therapy, treatment information including its side effects, and ordering treatment supplies related to the device. This team is available to our patients 24 hours a day, seven days a week.
Janice, living with glioblastoma in California
2026 Novocure corporate responsibility report 13
product innovation
As an innovative device manufacturer, we are focused on identifying ways to improve the components of our therapy system.
Our product development teams assess the daily activity of our patients to find areas where we may be able to improve the device. Understanding the true experience of our patients is vital to make meaningful improvements and has led to numerous improvements over the years.
investment ($m):
Jovan, living with glioblastoma in Minnesota
As an example, one of our recent product improvements has been the development of our next generation Head Flexible Electrode (HFE) arrays for use with Optune Gio. These arrays utilize new materials and were designed to provide a more comfortable therapy experience for patients. The HFE arrays are thinner, lighter and more flexible than previous array versions, and by the end of 2025 had been successfully rolled out to nearly all of our global markets.
In addition to hardware improvements, like the HFE arrays, we are also focused on daily use improvements for patients. The introduction of the MyNovocure app, which is used on patient and caregiver mobile devices, allows daily usage rates
to be tracked, troubleshooting of device issues, as well as access to educational videos and supply reordering. The MyNovocure app is available for use with Optune Gio, Optune Lua (NSCLC) and Optune Pax in the U.S., and it is also available for use with Optune Gio in France and Germany.
Our Product Development team is currently focused on several projects that could further improve TTFields therapy, including next generation arrays for use on the thorax and abdomen.
2025
2024
2023
2022
Product development $25.6
$18.2
$18.2
$15.3
2026 Novocure corporate responsibility report 14
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
Novocure employees in our offices in Kraków, Poland
employees
Employee Engagement
Performance Management
Talent Development
Employee Benefits
Hybrid Work
Safe Workplaces
2026 Novocure corporate responsibility report 15
The strength of our employees is directly connected to the care we can provide for our patients and all of our stakeholders.
The unique talents, diverse backgrounds and expansive experiences of our employees provide us with diverse perspectives that are key for our global business to succeed. We know that attracting, developing and retaining
a talented workforce remains paramount to our success, and we are committed to meeting the professional needs of our employees.
2026 Novocure corporate responsibility report
employee engagement
We aim to ensure our more than 1,500 employees have multiple avenues to relay feedback, present ideas, ask questions, and share concerns to senior management. Our goal is to make sure every voice has the opportunity to be heard.
Joana Lima, Quality Operations Lead
Employee engagement begins with each employee's onboarding process. This includes educational sessions focused on Novocure's culture and values, as well as TTFields therapy and the connection we have with our patients.
Throughout the onboarding process, new employees are encouraged to provide feedback to session leaders. In 2025, an onboarding survey, conducted approximately four months post-hire, assessed early employee experience and integration. We believe feedback from our newest employees provides a fresh, important perspective that can drive future improvement.
We traditionally hold at least one town hall per quarter, where our executive team addresses employees directly. Several presentations on key topics
are followed by an open forum for questions, including the opportunity to electronically and anonymously submit questions for those not attending
in-person. These town halls are an opportunity to address evolving issues or concerns, better understand our strategic direction, and engage directly with members of the executive team. We also hold local town hall sessions with members of the executive team.
We periodically survey our workforce. These surveys address a variety of topics, including feedback on employee benefits. The scope of surveys can encompass the entire workforce or smaller populations within certain functions or geographic regions. Aggregated, anonymous feedback from surveys is delivered to managers for analysis and discussion and leveraged to evaluate future improvements.
In 2025, we conducted a global employee survey, focused on overall engagement, satisfaction, and organizational culture. These surveys were designed to
provide actionable insights across the employee lifecycle, supporting ongoing improvements in employee experience and talent processes.
16
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
Novocure employees in our global headquarters in Baar, Switzerland
performance management
We believe clear and open feedback is necessary to support employees' professional growth, and that this process positions our employees for long-term success.
At Novocure, we utilize a structured goal setting and performance approach grounded in clear expectations, continuous feedback, and open dialogue.
At the beginning of each annual cycle, employees and managers partner to establish performance and development goals that are aligned with company priorities, our mission, and core values.
Employees draft their goals and engage in discussion with their managers to refine and align them with team and organizational objectives. We provide employees with a variety of educational resources to facilitate best practices for goal setting.
2026 Novocure corporate responsibility report
Throughout the year, employees and managers engage in regular performance conversations to discuss progress, share feedback, and adjust priorities as needed. These ongoing check-ins are central to our approach and reinforce a culture of continuous development and accountability.
As part of the annual cycle, employees complete a self-reflection on their progress and contributions, which informs a year-end performance discussion with their manager. This conversation provides an opportunity to recognize achievements, discuss development, and align on future growth.
17
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
talent development
We believe that cultivating leadership skills at every
level of our organization is vital to our long-term success. That's why we place a strong emphasis on identifying and nurturing future leaders through intentional, forward-looking talent development strategies.
Our learning and development platform NovoAcademy offers structured learning journeys that build leadership capability and accelerate growth. From foundational skills to advanced leadership, these experiences empower our people to lead
with purpose and impact. In 2025, NovoAcademy continued to grow and evolve, as the scope of our enterprise needs expand. Inside NovoAcademy programs, employees take part in a variety of sessions, including in-person classroom learning, experiential education, business issue projects, coaching and active learning.
In 2025, we concluded our NovoAcademy Enterprise Development Program for Senior Leaders, launched and graduated our first Advanced Leadership Program for Directors, and launched and graduated our first Management Development Program for Managers. More than 75 employees participated in these talent development programs. To help us continuously improve the programming, we solicited feedback from participants on key areas such as
content relevance, facilitation quality, practical application, overall experience, and impact on career growth.
We provide employees access to continuous learning content online, including LinkedIn Learning, ExecOnline, Culture Amp's Skills Coach, and our Learning Management System (LMS), supporting career growth, strengthening our leadership pipeline, and fostering a culture of learning and collaboration.
We offer educational and development opportunities to employees, including annual tuition reimbursement of up to $5,250 for successfully completed coursework. Employees are able to apply tuition reimbursement towards accepted coursework related to business-related certificate programs, associate's degrees, bachelor's degrees, or master's degrees. We believe this program allows
employees to explore and broaden their skillsets in a variety of ways to benefit their personal and professional development.
In addition to skill development, our Human Resources team conducts annual talent reviews across the organization, with a strong focus on succession planning for key talent and preparing for critical positions. This process includes the identification of future leaders, readiness assessments, and the creation of individual development plans to support career growth. Succession planning is also a priority at the Executive Leadership Team (ELT) level, ensuring leadership continuity and strategic talent development. Strategic learning and development initiatives play a key role in strengthening the succession pipeline by providing targeted training and skill-building opportunities.
NovoAcademy Advanced Leadership Program Participants, 2025 Cohort
2026 Novocure corporate responsibility report 18
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
employee benefits
We are committed to providing a high-quality, affordable, and diverse benefits package that addresses the needs of our workforce.
We believe competitive benefits can contribute to a positive corporate culture
Benefit availability is subject to employees' geographic location and employee status (full-time, part-time, temporary). The majority of our benefits are available to part-time and temporary workers that meet applicable work thresholds.
BENEFITS WE OFFER INCLUDE:
and can enable us to attract and retain talented individuals. We aim to provide employees with a variety of choices within the benefits package, including voluntary offerings that address diverse needs.
To ensure competitive compensation practices, our human resources team performs regular broad-based market analyses. These analyses compare our compensation and benefits packages to applicable peers across geographic regions where we are active. This practice enables us to remain at the forefront of competitive compensation and ensures our employees are fairly compensated for their unique skill sets. In addition to these analyses, our benefits management team solicits feedback from our employee base throughout the year.
Medical insurance
Dental insurance
Vision insurance
Health Savings Account (HSA)
Flexible Spending Account (FSA)
Life and disability insurance
Retirement savings plan with company match
Tuition reimbursement
Paid time-off, including floating
holidays
Paid parental leave, including maternity leave, paternity leave, adoption and foster care leave
NovoFit Wellness Program, including wellness stipend
Employee stock purchase plan with lookback feature
PERCENTAGE OF ELIGIBLE EMPLOYEES WHO PARTICIPATED
IN OUR EMPLOYEE SHARE PURCHASE PROGRAM
WORKFORCE BREAKDOWN
2025
2024
2023
2022
2021
Temporary (1%)
Full-Time (97%)
Part-time (2%)
40%
43%
63%
63%
68%
We believe ownership in Novocure should be shared among all of our employees. In addition to our employee share purchase plan, all full-time employees receive an equity award as part of their starting compensation package.
2026 Novocure corporate responsibility report 19
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
hybrid work
At Novocure, we believe work is about outcomes and building relationships with colleagues and stakeholders. To facilitate this, we announced our new hybrid work philosophy called "NovoFlex" in 2025.
This philosophy empowers employees with their managers to decide when and where they work best while fostering meaningful in-person connections with the goal of an average of at least three days a week in-person, prioritizing the use of our offices, throughout the year.
Novocure employees at the ribbon-cutting of our offices in Kraków, Poland
SHARE OF GLOBAL POSITIONS
90%
HELD BY WOMEN Female Male
41%
59%
2023
41%
59%
2024
42%
58%
2025
Employees
Manager-and-above
48%
Vice President
Executive
10
%
Board of Directors
70%
30%
64%
36%
70%
30%
87%
13%
50%
50%
48%
52%
100%
52%
34%
66%
34%
66%
36%
64%
2026 Novocure corporate responsibility report 20
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
2025
2024
2023
2022
2021
4 injuries
0 injuries
1 injury
0 injuries
1 injury
(0 serious injuries)
(0 serious injuries)
(0 serious injuries)
(0 serious injuries)
(0 serious injuries)
INJURIES SUFFERED IN THE WORKPLACE
safe workplaces
We are committed to providing all employees with physically, mentally and emotionally safe and secure work environments.
All global employees are required to complete regular health and safety training programs. Employees are trained annually on numerous safety topics,
including, but not limited to, the correct use and location of personal protective equipment (PPE), awareness of blood borne pathogens, fire safety, ergonomics, general first aid, lab safety procedures, chemical safety procedures, biosafety, and additional topics that may be relevant to specific roles. Additionally, we have
a designated Global Safety Committee and a designated safety officer in each of our global locations. We believe in creating emotionally and mentally safe environments for our employees. All employees are required to annually review and sign-off on our Code of Conduct, which includes policies against
discrimination and harassment at all times. Any discrimination or harassment on the basis of any protected characteristic is strictly prohibited. This prohibition includes verbal or physical conduct that denigrates or shows hostility or aversion toward an individual because of their race, color, religion, national origin, ancestry, age, physical or mental disability, gender, sexual orientation, pregnancy, genetic information, veteran status or any other characteristic protected by
Novocure employees in our global headquarters in Baar, Switzerland
law. Additionally, physical or verbal conduct that creates an intimidating, hostile or offensive work environment, unreasonably interferes with an individual's work performance, or otherwise adversely affects an individual's employment opportunities is strictly prohibited.
All employees are required to review, abide by, and sign-off on safety policies and procedures on an annual basis. This includes, but is not limited to, policies governing ethical business practices, compliance, reporting and investigation of alleged issues, protection from retaliation, discrimination and harassment, sexual harassment, privacy protection, conflicts of interest, intellectual property, social media, insider trading, records management, political contributions, interactions with healthcare professionals and patients, advertising and marketing, anti-corruption and bribery.
2026 Novocure corporate responsibility report 21
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
Mike, living with glioblastoma in Florida
communities & environment
Charitable Giving
Advocacy
Grants
Environmental Stewardship
2026 Novocure corporate responsibility report 22
Novocure employees in Germany donating gifts for needy children.
Novocure employees volunteering at a food pantry in Portsmouth, NH
We believe we have a responsibility to act as
a trusted and ethical partner with all our stakeholders. This includes the communities in which our employees, patients, caregivers and families live and work.
charitable giving
Through the Novocure Charitable Giving Program, we strive to support patients, strengthen local communities, and advance broader social impact priorities in the areas where we live and work.
Novocure's 2025 charitable giving budget was $750,000, with a defined set of giving priorities intended to balance healthcare-related support, community investment, employee participation, and flexible response to emerging needs. We direct our giving with the intent of creating meaningful impact that addresses critical needs and supports initiatives and groups aligned with our patient-forward mission.
Novocure's charitable giving program is overseen by our Charitable Review Committee. The Committee consists of key contributors from across multiple business units, seniority levels, and geographic locations. The governance process includes four stages: submission through a central portal, regional review, quarterly committee approval, and execution with agreement, tracking, and impact monitoring. A formal review process with cross-functional contributions is designed to promote consistency, oversight, and alignment with company priorities.
Any Novocure employee can submit a charitable contribution proposal for review.
In 2025, one focus was science, technology, engineering and mathematics (STEM) initiatives, with an expanded after-school "STEAM" programming for underprivileged students and sponsored educational opportunities to support
our future workforce.
Our approach integrates charitable giving with community engagement and volunteerism to ensure a lasting impact in areas that reflect our core mission and values. In 2025, we expanded volunteer opportunities for employees at local food banks, and at gift donation events for children in need.
2026 Novocure corporate responsibility report 23
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
advocacy
Inspired by the resilience and dedication of our patients worldwide,
we support advocacy organizations aligned with our patient-forward mission, our company vision and our values.
In 2025, we sponsored and participated in numerous events to support cancer communities, collaborating with patient groups and professional organizations globally and regionally. Our partnerships are purposeful and action-driven.
Optune Gio users and their caregivers, pictured with Novocure employees at the ABTA National Conference
2025 ADVOCACY HIGHLIGHTS
ABTA National Conference
We were proud to support the American Brain Tumor Association (ABTA) Annual National Conference in Chicago, where more than 1,300 brain tumor patients, caregivers, and their families gathered in person and virtually to connect with one another and hear from leading physicians and advocates. A cross-functional team from Novocure was on the ground with glioblastoma patients of different ages, healthcare providers, and patient
advocacy organization leaders, building connections that help us to better meet the needs of the glioblastoma community.
Lung Cancer Community Walks
We expanded our commitment to the lung cancer community by supporting and participating in 15 walks across 13 U.S. cities. Community walks hosted by trusted patient advocacy organizations offered our employees the chance to stand shoulder to shoulder with patients, families, and caregivers in their own cities, united by a shared experience. These events, hosted by major lung cancer organizations including LUNGevity, GO2 for Lung Cancer, the Lung Cancer Research Foundation, and the American
Lung Association build local community and raise awareness of lung cancer.
Pancreatic Cancer Partnership
We continued to deepen our connection to the pancreatic cancer community through a
collaboration with the Pancreatic Cancer Action Network (PanCAN), among other organizations. We joined a working group with patients and survivors to better understand the experiences and needs of individuals and their families after a pancreatic cancer diagnosis. Novocure employees
and their families also joined more than 4,000 other families and advocates who participated in the PurpleStride walk events in Philadelphia and Boston.
2026 Novocure corporate responsibility report 24
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
INTRODUCTION OVERVIEW PATIENTS EMPLOYEES COMMUNITIES & ENVIRONMENT CORPORATE GOVERNANCE & ETHICS QUALITY & SAFETY APPENDIX
grants
We are dedicated to supporting independent organizations with shared goals and values related to advancing medical care and improving patient outcomes
through education grants, career development awards, research grant awards and investigator-sponsored trials. These contributions also include funding for external organizations in support of requests for independent, unbiased, scientific, medical and patient activities.
When making funding decisions, we account for a number of factors, including alignment with our core values and mission, as well as commitment to ethical business practices. Only funding requests that comply with all applicable local, state, regional, national, and international codes, guidelines and laws will be considered.
Actor Portrayal
We have partnered with the American Association for Cancer Research since 2019 to provide research grants focused on the further development of TTFields therapy. This joint effort supports innovative research seeking to pursue a deeper understanding of the mechanisms of action of TTFields and accelerating the development of new treatment strategies. These collaborations help deepen the understanding of our therapy and identify potential future use cases.
2026 Novocure corporate responsibility report
2025 AACR-NOVOCURE GRANTEES
Zhaohui Wang, PhD
Leveraging TTFields to overcome resistance to vorasidenib in IDH-mutant gliomas, a form of brain cancer
Ioannis Verginadis, MSc, PhD
Therapeutic potential of combining Tumor Treating Fields (TTFields) with radiation therapy and immunotherapy in pancreatic cancer
Milan Girish Chheda, MD
Enhancing TTFields efficacy with oncolytic Zika virus therapy in glioblastoma, an aggressive form of brain cancer
Illustration of TTFields affecting a cancer cell during cell devision
25
environmental stewardship
We believe in doing our part to minimize the environmental impact of
our operations whenever possible, keeping a balance between operational efficiency and environmental impact.
SUSTAINABLE WORKPLACE
We utilize a number of techniques and technology to decrease the footprint of our global workspace. This includes efforts to minimize waste and decrease consumption. We utilize motion-activated, LED lighting systems in all of our offices to consume less energy. We also employ energy efficient heating, ventilation, and air conditioning systems.
GREENHOUSE GAS REPORTING
We are advancing the measurement of our environmental footprint by mapping Scope 1 and Scope 2 greenhouse gas emissions for 2025, as part of Novocure's broader commitment to improving sustainability, governance, and compliance across its global operations.
2026 Novocure corporate responsibility report 26
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
PACKAGING AND WASTE MINIMIZATION
We have initiated a global packaging mapping project to align with emerging regulatory requirements, including the upcoming EU Packaging and Packaging Waste Regulation (PPWR), and to advance its broader sustainability objectives. We are working closely with key suppliers to collect detailed packaging data, assess current materials and formats, and identify opportunities for optimization across the supply chain. We are defining a phased roadmap, starting in 2027,
to redesign packaging solutions, prioritizing high-impact areas and ensuring alignment with regulatory timelines. This includes evaluating alternative materials, reducing unnecessary packaging, and improving end-of-life recyclability. The initiative is expected to reduce environmental impact, improve compliance readiness for PPWR, and enhance supply chain transparency.
We follow international guidelines for the disposal of electronic waste. We also follow more stringent local laws and regulations in applicable jurisdictions.
Our efforts to minimize our carbon footprint, reduce transportation and travel, and protect valuable natural resources while operating a global business include:
Sourcing most of our packaging material locally
Re-using shipping boxes when possible
Using virtual communication and collaboration platforms and offering remote patient support to minimize travel
Re-using or repurposing, as appropriate, returned or unused equipment in accordance with relevant safety standards
All electronic waste including scrapped equipment and unused arrays is recycled through partners that are ISO 14001 certified. Novocure recycles all relevant materials in accordance with established safety, health and environmental standard operating procedures.
STANDARDS FOR OUR SUPPLIERS
Our Supplier Code of Conduct sets expectations for our suppliers regarding environmental responsibility, regulatory compliance, and continuous improvement. In 2025, we further strengthened this Code of Conduct to better align with evolving sustainability standards. We are collaborating with key suppliers on specific initiatives, including packaging data collection and redesign efforts in preparation for the EU PPWR regulation, with a focus on reducing material usage and improving recyclability. We are also enhancing our supplier assessment and audit processes to better integrate environmental considerations into supplier evaluation and ongoing performance management. These efforts reflect our commitment to working collaboratively with suppliers to reduce environmental impact across our value chain.
2026 Novocure corporate responsibility report 27
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
William Doyle, Executive Chairman
corporate
governance & ethics
Corporate Responsibility Oversight
Board of Directors
Compliance
Code of Conduct
Government Affairs
Ethical Interactions with Healthcare Professionals
Bribery and Corruption
Clinical Trials
Animal Testing Policy
Data Security
Integrity Hotline
Compliance Corrective Action
Global Supplier Governance
2026 Novocure corporate responsibility report 28
INTRODUCTION OVERVIEW PATIENTS EMPLOYEES COMMUNITIES & ENVIRONMENT CORPORATE GOVERNANCE & ETHICS QUALITY & SAFETY APPENDIX
We are committed to acting in accordance with the highest levels of corporate governance, oversight, and ethics. We are committed to maintaining strong corporate governance and compliance principles in all aspects of our business.
We proactively seek out, engage with, and solicit feedback from our stakeholders and consider their independent oversight of management and our long-term strategy to deliver value. As part of our commitment to constructive engagement practices with shareholders, we evaluate and respond to the views voiced by
our shareholders. This ongoing dialogue has led to enhancements in areas such as corporate governance, corporate responsibility practices, and executive
compensation activities, which we believe are in the best interests of our business and stakeholders, including patients, caregivers, shareholders, and employees.
corporate responsibility oversight
Our Board of Directors is structured to enable comprehensive oversight of key aspects of our business activities, including ethics and responsibility. Each
of our Board's committees has an active role in reviewing areas of our business to ensure we act in compliance with our robust controls and with the highest ethical standard.
The Nominating and Corporate Governance Committee has broad oversight over our corporate governance procedures. This includes, but is not limited
to, safety, quality, legal compliance, and charitable giving activities. Additionally, the Nominating and Corporate Governance Committee has oversight over corporate responsibility strategy and reporting activities, including disclosure process and engagements with stakeholders.
The Audit Committee oversees and receives quarterly updates on items associated with internal control structure, internal audit function, integrated enterprise risk management, data privacy and cybersecurity. The Compensation Committee oversees compensation plans, succession planning, and employee benefits. At the Executive level, our Chief Financial Officer, Christoph Brackmann, leads the Corporate Responsibility Management Committee.
2026 Novocure corporate responsibility report 29
corporate responsibility oversight (cont.)
BOARD OF DIRECTORS
BEST PRACTICES INDEPENDENCE
Shareholder engagement program
Board oversight of corporate responsibility
Board oversight of corporate strategy and risk
Stock ownership guidelines for executive officers and directors
Orientation program for new directors
Continuing education for directors
Periodic Board refreshment
Anti-hedging and anti-pledging policies
Separate Executive Chairman of the Board and CEO positions
73% of our Board members are independent
All committee members are independent
Independent Lead Director with defined responsibilities
ACCOUNTABILITY
Annual Board and Committee self-evaluations
Clawback policy
Director resignation policy
Annual CEO evaluation by independent directors
SHAREHOLDER PROTECTIONS
One vote per share
No poison pill
No dual-class common stock
Annual election of directors
73%
OF OUR BOARD MEMBERS ARE INDEPENDENT
60
27%
OF OUR BOARD MEMBERS IDENTIFY AS WOMEN
9.7
73%
OF DIRECTORS HAVE INTERNATIONAL EXPERIENCE
45%
HIGHLY QUALIFIED DIRECTORS REFLECT BROAD MIX OF BUSINESS BACKGROUNDS, SKILLS AND EXPERIENCES
AVERAGE AGE OF DIRECTORS
AVERAGE TENURE
OF DIRECTORS (YEARS)
OF DIRECTORS HAVE EXPERIENCE AS A PUBLIC COMPANY CEO OR EXECUTIVE CHAIR IN THE PAST FIVE YEARS
2026 Novocure corporate responsibility report 30
INTRODUCTION
OVERVIEW
PATIENTS
EMPLOYEES
COMMUNITIES & ENVIRONMENT
CORPORATE GOVERNANCE & ETHICS
QUALITY & SAFETY
APPENDIX
Disclaimer
Novocure Ltd. published this content on April 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 21, 2026 at 14:51 UTC.